UBS Sees Growing Risks to Cochlear’s Fiscal 2028 Earnings Recovery
UBS analysts say Advanced Bionics’ new implant platform is another incremental headwind for Cochlear, putting consensus forecasts for a fiscal 2028 earnings recovery at risk.
UBS analysts say Advanced Bionics’ new implant platform is another incremental headwind for Cochlear, putting consensus forecasts for a fiscal 2028 earnings recovery at risk.